WST · 10-Q · 2026Q3 · Full report

Operating Profit and Margins

WEST PHARMACEUTICAL SERVICES INC · 2026-10-29 · Importance 69 · Surprise 64 · In source text

Consolidated GAAP operating profit increased 59.5% to $267.4 million in the third quarter of 2026 and 45.6% to $623.6 million in the first nine months; reported operating margins were 30.6% and 24.1%, respectively. Adjusted operating profit rose 30.2% to $221.5 million in the quarter and 33.2% to $599.9 million over nine months, with adjusted margins of 25.3% and 23.1%. Proprietary Products operating profit increased 31.6% to $230.6 million in the quarter and 35.1% to $631.7 million over nine months, principally from favorable HVP components mix, including GLP-1 products. West Vantage operating profit fell 30.5% to $15.5 million in the quarter and 17.9% to $44.0 million over nine months, primarily due to production inefficiencies, including downtime related to the May 2026 cyber incident, and inflationary plant spending.

Key facts

• WEST PHARMACEUTICAL SERVICES INC’s consolidated operating profit increased $99.8 million, or 59.5%, in the three months ended September 30, 2026, and $195.3 million, or 45.6%, in the nine months ended September 30, 2026. source
• WEST PHARMACEUTICAL SERVICES INC’s West Vantage operating profit decreased $9.6 million, or 17.9%, in the nine months ended September 30, 2026, mainly due to production downtime related to the May 2026 cyber incident and inflationary plant spend. source
• WEST PHARMACEUTICAL SERVICES INC’s West Vantage operating profit decreased $6.8 million, or 30.5%, in the three months ended September 30, 2026, mainly due to production inefficiencies and inflationary plant spend. source
• WEST PHARMACEUTICAL SERVICES INC recorded $3.5 million of cost-method investment impairment charges during the nine months ended September 30, 2026. source

Impact estimates